• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

健康成年参与者中更高剂量卡泊芬净的安全性和药代动力学。

Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants.

机构信息

Merck Research Laboratories, PO Box 2000, RY34-A500, Rahway, NJ, USA.

出版信息

J Clin Pharmacol. 2011 Feb;51(2):202-11. doi: 10.1177/0091270010374853. Epub 2010 Aug 2.

DOI:10.1177/0091270010374853
PMID:20679501
Abstract

Caspofungin was the first in a new class of antifungal agents (echinocandins) indicated for the treatment of primary and refractory fungal infections. Higher doses of caspofungin may provide another option for patients who have failed caspofungin or other antifungal therapy. This study evaluated the safety, tolerability, and pharmacokinetics of single 150- and 210-mg doses of caspofungin in 16 healthy participants and 100 mg/d for 21 days in 20 healthy participants. Other than infusion site reactions and 1 reversible elevation in alanine aminotransferase (≥2× and <4× upper limit of normal), caspofungin was generally well tolerated. Geometric mean AUC(0-∞) after single 150- and 210-mg doses was 279.7 and 374.9 µg·h/mL, respectively; peak concentrations were 29.4 and 33.5 µg/mL, respectively; and 24-hour postdose concentrations were 2.8 and 4.2 µg/mL, respectively. Steady state was achieved in the third week of dosing. Following multiple 100-mg doses of caspofungin, day 21 geometric mean AUC(0-24) was 227.4 µg·h/mL, peak concentration was 20.9 µg/mL, and trough concentration was 4.7 µg/mL. Beta-phase t(1/2) was ~8 to ~13 hours. Caspofungin pharmacokinetics at these higher doses were dose proportional to and consistent with those observed at lower doses, suggesting a modest nonlinearity of increased accumulation with dose, which was considered not clinically meaningful.

摘要

卡泊芬净是首个新型抗真菌药物(棘白菌素类),适用于治疗原发性和复发性真菌感染。对于卡泊芬净或其他抗真菌治疗失败的患者,较高剂量的卡泊芬净可能是另一种选择。本研究评估了 16 名健康受试者单次接受 150 毫克和 210 毫克剂量,以及 20 名健康受试者连续 21 天每天接受 100 毫克剂量的卡泊芬净的安全性、耐受性和药代动力学。除了输注部位反应和 1 例丙氨酸氨基转移酶升高(≥2×和<4×正常值上限)外,卡泊芬净总体上耐受性良好。单次 150 毫克和 210 毫克剂量后的几何平均 AUC(0-∞)分别为 279.7 和 374.9µg·h/mL;峰浓度分别为 29.4 和 33.5µg/mL;24 小时后浓度分别为 2.8 和 4.2µg/mL。在第三周给药时达到稳态。多次给予 100 毫克剂量的卡泊芬净后,第 21 天的几何平均 AUC(0-24)为 227.4µg·h/mL,峰浓度为 20.9µg/mL,谷浓度为 4.7µg/mL。β 相 t(1/2)约为 8 至 13 小时。这些较高剂量的卡泊芬净药代动力学与较低剂量观察到的情况呈剂量比例,表明剂量增加时的蓄积呈适度非线性,这被认为无临床意义。

相似文献

1
Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants.健康成年参与者中更高剂量卡泊芬净的安全性和药代动力学。
J Clin Pharmacol. 2011 Feb;51(2):202-11. doi: 10.1177/0091270010374853. Epub 2010 Aug 2.
2
Phase II dose escalation study of caspofungin for invasive Aspergillosis.卡泊芬净治疗侵袭性曲霉病的 II 期剂量递增研究。
Antimicrob Agents Chemother. 2011 Dec;55(12):5798-803. doi: 10.1128/AAC.05134-11. Epub 2011 Sep 12.
3
Plasma concentrations of caspofungin at two different dosage regimens in a patient with hepatic dysfunction.一名肝功能不全患者在两种不同给药方案下的卡泊芬净血浆浓度。
Transpl Infect Dis. 2012 Aug;14(4):440-3. doi: 10.1111/j.1399-3062.2011.00716.x. Epub 2012 Feb 9.
4
Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.卡泊芬净在健康男性中的单剂量和多剂量药代动力学。
Antimicrob Agents Chemother. 2002 Mar;46(3):739-45. doi: 10.1128/AAC.46.3.739-745.2002.
5
Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age.卡泊芬净在新生儿及3个月以下婴儿中的药代动力学和安全性。
Antimicrob Agents Chemother. 2009 Mar;53(3):869-75. doi: 10.1128/AAC.00868-08. Epub 2008 Dec 15.
6
Lack of pharmacokinetic drug interaction between oral posaconazole and caspofungin or micafungin.泊沙康唑口服制剂与卡泊芬净或米卡芬净之间不存在药代动力学药物相互作用。
J Clin Pharmacol. 2011 Jan;51(1):84-92. doi: 10.1177/0091270009360982. Epub 2010 May 20.
7
A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis.一项针对成年侵袭性念珠菌病患者的高剂量卡泊芬净治疗方案与标准卡泊芬净治疗方案的多中心双盲试验。
Clin Infect Dis. 2009 Jun 15;48(12):1676-84. doi: 10.1086/598933.
8
Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.评估卡泊芬净或米卡芬净作为成人持续性发热性中性粒细胞减少症患者经验性抗真菌治疗的效果:回顾性、观察性、连续队列分析。
Clin Ther. 2010 Apr;32(4):637-48. doi: 10.1016/j.clinthera.2010.04.005.
9
Pharmacokinetics and safety of caspofungin in older infants and toddlers.卡泊芬净在婴幼儿中的药代动力学及安全性
Antimicrob Agents Chemother. 2009 Apr;53(4):1450-6. doi: 10.1128/AAC.01027-08. Epub 2008 Dec 29.
10
Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits.抗真菌棘白菌素类药物卡泊芬净(MK-0991)在兔体内的房室药代动力学。
Antimicrob Agents Chemother. 2001 Feb;45(2):596-600. doi: 10.1128/AAC.45.2.596-600.2001.

引用本文的文献

1
Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis.延迟治疗福司莫吉哌(APX001)在念珠菌属耳念珠菌侵袭性念珠菌病小鼠模型中的疗效。
Antimicrob Agents Chemother. 2019 Oct 22;63(11). doi: 10.1128/AAC.01120-19. Print 2019 Nov.
2
Efficacy of humanized single large doses of caspofungin on the lethality and fungal tissue burden in a deeply neutropenic murine model against and .人源化单剂量大剂量卡泊芬净对严重中性粒细胞减少小鼠模型中针对[具体真菌名称1]和[具体真菌名称2]的致死率及真菌组织负荷的疗效。 (你原文中against后内容缺失,以上是补充完整后的大致译文)
Infect Drug Resist. 2019 Jul 1;12:1805-1814. doi: 10.2147/IDR.S198764. eCollection 2019.
3
Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration.
连续性静脉-静脉血液滤过或血液透析滤过的危重症患者中卡泊芬净群体药代动力学。
Clin Pharmacokinet. 2017 Sep;56(9):1057-1068. doi: 10.1007/s40262-016-0495-z.
4
Dose escalation studies with caspofungin against Candida glabrata.卡泊芬净针对光滑念珠菌的剂量递增研究。
J Med Microbiol. 2015 Sep;64(9):998-1007. doi: 10.1099/jmm.0.000116. Epub 2015 Jun 30.
5
Physiology-based pharmacokinetics of caspofungin for adults and paediatrics.卡泊芬净在成人和儿童中的基于生理学的药代动力学。
Pharm Res. 2015 Jun;32(6):2029-37. doi: 10.1007/s11095-014-1595-9. Epub 2014 Dec 19.
6
Application of caspofungin in China compared with amphotericin B and fluconazole.卡泊芬净在中国的应用与两性霉素 B 和氟康唑的比较。
Ther Clin Risk Manag. 2014 Sep 10;10:737-41. doi: 10.2147/TCRM.S47146. eCollection 2014.
7
Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis.在一项侵袭性曲霉菌病患者的 II 期研究中,对递增剂量卡泊芬净的群体药代动力学研究。
Antimicrob Agents Chemother. 2013 Apr;57(4):1664-71. doi: 10.1128/AAC.01912-12. Epub 2013 Jan 18.
8
Comparison of in vitro and vivo efficacy of caspofungin against Candida parapsilosis, C. orthopsilosis, C. metapsilosis and C. albicans.棘白菌素类药物卡泊芬净抗近平滑念珠菌、近平滑念珠菌、中间型念珠菌和白念珠菌的体外与体内药效比较。
Mycopathologia. 2012 Oct;174(4):311-8. doi: 10.1007/s11046-012-9554-7. Epub 2012 May 8.
9
Effect of fluid loading during hypovolaemic shock on caspofungin pharmacokinetic parameters in pig.低血容量性休克时液体复苏对猪体内卡泊芬净药代动力学参数的影响。
Crit Care. 2011;15(5):R219. doi: 10.1186/cc10455. Epub 2011 Sep 20.
10
Phase II dose escalation study of caspofungin for invasive Aspergillosis.卡泊芬净治疗侵袭性曲霉病的 II 期剂量递增研究。
Antimicrob Agents Chemother. 2011 Dec;55(12):5798-803. doi: 10.1128/AAC.05134-11. Epub 2011 Sep 12.